BII is proud to announce the establishment of the Women’s Health Innovation Panel (WHIP) to support our strategic initiative in women’s health. The new panel will lend its expertise to facilitate the assessment of BII Venture Lab and Bio Studio program applications in women’s health and advise BII in developing its women’s health strategy and relevant ecosystem-building activities. The WHIP brings together renowned experts and perspectives from across the innovation pipeline, including leading academics, VCs, entrepreneurial experts, and key industry representatives. 

Trine Bartholdy, Chief Innovation Officer, BII: “We are both excited and profoundly grateful to have gathered this fantastic panel of highly experienced and world-leading researchers, investors, entrepreneurs, and industry professionals. The combined set of unique insights and experience is essential to support and accelerate our mission of getting more solutions that address the high unmet needs of 50% of the world’s population to the market.”  

Women’s Health Innovation Panel members: 

Academics:  

Aris Papageorghiou, Professor of Fetal Medicine, Oxford University  

Linda Griffith, Professor of Biological and Mechanical Engineering, MIT  

VCs and Experts: 

Chandra P. Leo, Investment Advisor, HBM Partners 

Laetitia Schwab, Associate, SR One 

Mary Kerr, CEO, NeRRe Therapeutics  

Pam Garside, Chair, Cambridge Angels and Fellow, Judge Business School, University of Cambridge  

Stasia Obremskey, Managing Director, RH Capital  

Industry:  

Marcel van Duin, VP, Head of External Innovation and Emerging Science, Chief Scientific Officer, Organon 

Kelle Moley, VP of Science & Public Affairs / Rebecca Forster, Senior Director, External Innovation and Licensing, Ferring Pharmaceuticals